Inhibrx Biosciences, Inc. (INBX)

NASDAQ: INBX · Real-Time Price · USD

64.92

+1.39 (2.19%)

Apr 6, 2026, 1:15 PM EDT - Market open

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Biologic Therapeutic Candidates	1.30M	200.00K	1.80M	1.32M	7.23M
Biologic Therapeutic Candidates Growth	550.00%	-88.89%	36.88%	-81.81%	-43.89%
Total	1.30M	200.00K	1.80M	1.32M	7.23M
Total Growth	550.00%	-88.89%	36.88%	-81.81%	-43.89%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
United States	1.30M	200.00K	1.80M	1.32M	7.23M
United States Growth	550.00%	-88.89%	36.88%	-81.81%	-43.89%
Total	1.30M	200.00K	1.80M	1.32M	7.23M
Total Growth	550.00%	-88.89%	36.88%	-81.81%	-43.89%

Source: S&P Global Market Intelligence.